- Home
- INGN vs BDTX Comparison
INGN vs BDTX Comparison
Compare INGN & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INGN
- BDTX
- Stock Information
- Founded
- INGN 2001
- BDTX 2014
- Country
- INGN United States
- BDTX United States
- Employees
- INGN N/A
- BDTX N/A
- Industry
- INGN Industrial Specialties
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INGN Health Care
- BDTX Health Care
- Exchange
- INGN Nasdaq
- BDTX Nasdaq
- Market Cap
- INGN 219.3M
- BDTX 181.4M
- IPO Year
- INGN 2014
- BDTX 2020
- Fundamental
- Price
- INGN $8.69
- BDTX $3.99
- Analyst Decision
- INGN Strong Buy
- BDTX Strong Buy
- Analyst Count
- INGN 3
- BDTX 5
- Target Price
- INGN $11.00
- BDTX $12.00
- AVG Volume (30 Days)
- INGN 185.5K
- BDTX 1.0M
- Earning Date
- INGN 11-06-2025
- BDTX 11-04-2025
- Dividend Yield
- INGN N/A
- BDTX N/A
- EPS Growth
- INGN N/A
- BDTX N/A
- EPS
- INGN N/A
- BDTX 0.25
- Revenue
- INGN $343,472,000.00
- BDTX $70,000,000.00
- Revenue This Year
- INGN $7.93
- BDTX N/A
- Revenue Next Year
- INGN $8.18
- BDTX N/A
- P/E Ratio
- INGN N/A
- BDTX $15.96
- Revenue Growth
- INGN 5.15
- BDTX N/A
- 52 Week Low
- INGN $5.70
- BDTX $1.20
- 52 Week High
- INGN $12.91
- BDTX $4.10
- Technical
- Relative Strength Index (RSI)
- INGN 58.20
- BDTX 69.63
- Support Level
- INGN $8.24
- BDTX $3.81
- Resistance Level
- INGN $8.84
- BDTX $4.03
- Average True Range (ATR)
- INGN 0.32
- BDTX 0.20
- MACD
- INGN -0.03
- BDTX 0.04
- Stochastic Oscillator
- INGN 61.49
- BDTX 91.58
About INGN Inogen Inc
Inogen Inc is a medical technology company that develops and manufactures portable oxygen concentrators used to deliver oxygen therapy to patients with chronic respiratory conditions. Its key product, the Inogen One system, is a lightweight alternative to traditional, stationary oxygen concentrator systems and oxygen tanks. The firm sells its products to home medical equipment providers and also rents products directly to patients. Internationally, It sells its products through distributors large gas companies, and home oxygen providers. It generates the majority of its revenue in the United States.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.